French pharma group Sanofi abandons Covid-19 drug trials


Sanofi has announced that Kevzara, a drug originally developed with US pharma firm Regeneron for treating arthritis, has failed Phase 3 tests of its effectiveness in treating severe cases of Covid-19 and which involved 420 patients in several countries.

Reading articles is for subscribers only. Subscribe now.

French pharma giant Sanofi announced Tuesday it was halting trials for its rheumatoid arthritis drug Kevzara after it failed to prove an effective treatment for Covid-19, reports Radio France Internationale.